Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Shining a light on molecular mechanisms that potentiate phagocytosis of bacteria (ImmunoSynergy)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Immunity, Infection and I mmunotherapy
Panel description: The immune system , related disorders  and their mechanisms , biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases , innovative imm unological tools and approaches , including  therapies
Countries involved: United Kingdom
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2026-01-01
End date: 2030-12-31
Duration (months): 60.0
Total project cost (EUR): 2495392.08
EU funding (EUR): 2495392.08
Participants: 1
Project status: SIGNED

Antibiotics are among the greatest medical achievements of the 20th century and have significantly extended human lifespan. Nevertheless, bacterial infectious diseases continue to be a leading cause of death worldwide. Antibiotic treatment failures are common and typically linked to antimicrobial resistance (AMR), though resistance genes are not always present in such cases. Innate immune cells, particularly phagocytes serve as the first line of defence against infection, but they can paradoxically become reservoirs for certain pathogens. Within host cells, these bacteria are shielded from many antibiotic classes and may adopt persister phenotypes that confer tolerance, enabling them to survive phagocytosis and reinfect patients. My conviction is that tackling AMR and tolerance requires sophisticated approaches, where we need to find complementary pathways between immune response and antibiotic activity. Recent advances in super-resolution imaging will allow me to scrutinise molecular mechanisms in both host and pathogen that directly influence the outcome of phagocytosis. I propose to i), develop a super-resolution model of phagocytosis, using major AMR pathogen Staphylococcus aureus and host Drosophila melanogaster, to provide ground-breaking insights into the mechanisms of infection; ii), investigate how bacteria coordinate the cell cycle during infection, to identify vulnerabilities and test strategies to kill the internalised pathogens and iii), explore the roles of the host centrosome during phagocytosis, to determine how this organelle regulates the cytoskeleton and assess its potential as a target for immunomodulation. I will harness cutting-edge imaging technology to significantly advance the field of host-pathogen interactions. My main objective is to identify molecular targets and pathways that potentiate phagocytosis of bacteria and use that knowledge to develop synergistic therapies, which I hope can help reduce the global burden of AMR.

Keywords: phagocytosis,super resolution microscopy,cell wall,centrosomes,cytoskeleton
AI Driven industrial Equipment product life cycle boosting Agility, Sustainability and resilience (AIDEAS)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Industry
Destination: Climate neutral, Circular and Digitised Production
Action type: Innovation actions
Partnership: AI-DATA-ROBOTICS, Made in Europe (co-programmed)
Countries involved: Greece,Spain,Portugal,Finland,Italy,Germany,Slovenia,Poland
Call: Artificial Intelligence for sustainable, agile manufacturing (AI, Data and Robotics - Made in Europe Partnerships) (IA) (HORIZON-CL4-2021-TWIN-TRANSITION-01, 2021)
Start date: 2022-10-01
End date: 2025-09-30
Duration (months): 36.0
Total project cost (EUR): 6610338.75
EU funding (EUR): 5999694.0
Participants: 17
Project status: SIGNED

Machinery industry in Europe is a basis for employment, growth and wealth, with around 3.2 million people employed. Industrial equipment is considered a key enabler for industrial development and the EU has a historically strategic position in this sector. However, it lives from a technological edge in a very competitive landscape. Hereby, it is crucial to provide all stakeholders of the EU with AI technologies that guarantee a resilient design, deployment and reuse of industrial equipment for an increased global competitiveness and a reinforcement of its industrial strategic autonomy and resiliency. AIDEAS will develop AI technologies for supporting the entire lifecycle (design, manufacturing, use, and repair/reuse/recycle) of industrial equipment as a strategic instrument to improve sustainability, agility and resilience of the European machinery manufacturing companies. AIDEAS will deploy 4 integrated Suites: 1) Design: AI technologies, integrated with CAD/CAM/CAE systems, for optimising the design of industrial equipment structural components, mechanisms and control components; 2) Manufacturing: AI technologies for industrial equipment purchased components selection and procurement, manufactured parts processes optimisation, operations sequencing, quality control and customisation; 3) Use: AI technologies with added value for the industrial equipment user, providing enhanced support for installation and initial calibration, production, quality assurance and predictive maintenance for working on optimal conditions; 4) Repair-Reuse-Recycle: AI technologies for extending the useful life of machines through prescriptive maintenance (repair), facilitating a second life for machines through a smart retrofitting (reuse) and identification of the most sustainable end-of-life (recycle). The AIDEAS Solutions will be demonstrated in 4 Pilots of machinery manufacturers that provide industrial equipment to different industrial sectors: metal, stone, plastic and food.

Keywords: artificial intelligence,industrial equipment design,industrial equipment manufacturing,industrial equipment use,industrial equipment repair reuse recycle,agility,sustainability,resilience
Elucidation of risk factors and health determinants associated with PROGRESSION of Monoclonal Gammopathies to Multiple Myeloma (ELMUMY)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Mission
Theme: Cancer
Destination: Cancer
Action type: Research and Innovation actions
Countries involved: Greece,Italy,Spain,Germany,France,Cyprus
Call: Better understanding of the impact of risk factors and health determinants on the development and progression of cancer (HORIZON-MISS-2021-CANCER-02, 2021)
Start date: 2023-01-01
End date: 2026-12-31
Duration (months): 48.0
Total project cost (EUR): 9951078.19
EU funding (EUR): 9951078.19
Participants: 14
Project status: SIGNED

Multiple Myeloma is a chronic malignancy characterized by slow progression and recurrences. Currently there is no effective cure since eventually the disease develops resistance to all the available therapeutic approaches. Although recent advances have expanded our understanding of the cellular functions associated with health to disease transition, recurrence and response to therapy, critical aspects of this complex pathology remain to be elucidated. Application of omics technologies, and bioinformatics approaches on highly annotated samples obtained from all informative states (monoclonal gammopathy of undetermined significance [MGUS], smoldering MM [sMM], active MM [MM]) could identify biological pathways and molecules responsible for the onset, progression and resistance to therapy of Multiple Myeloma. In parallel, particular emphasis will be given to elucidating the health determinants and risk factors associated with progression to active MM from MGUS/sMM by using extensive demographic, lifestyle and exposure datasets. MGUS is present in 3-5% of the ageing European population and every year, 1% progress to incurable MM that imposes a significant burden on EU societies and health systems. Thus, the best chances of curing MM may be in preventing its progression in the first place. Moreover, there is need of experimental models that recapitulate myeloma progression. We propose an interdisciplinary approach bringing together clinicians and researchers aiming to integrate epidemiological, clinical and experimental datasets in order to create a molecular model of cellular processes associated with the onset of active MM and response to therapy. The proposed systems medicine approach could yield clinically actionable molecular features that could improve MM patient management. Moreover, the integration of lifestyle, clinical and omics information will provide specific profiles for each patient allowing personalized diagnosis, prevention, and therapeutic approaches. This action is part of the Cancer Mission cluster of projects on ''Understanding'.

Keywords: multiple myeloma,systems medicine,proteomics,transcriptomics
COLDSPARK® PHASE II: “UNLOCKING SCALABLE AND AFFORDABLE H2 AND ELEMENTAL CARBON AS CRITICAL RAW MATERIALS FOR THE EU” (ColdSpark Phase II)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Norway
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 2450000.0
EU funding (EUR): 2450000.0
Participants: 1
Project status: CLOSED

ColdSpark® Phase II builds on the Horizon Europe-funded ColdSpark® project (No. 101069931) to demonstrate a sustainable, low-temperature (<300 °C, <3 bar), catalyst-free methane and biomethane splitting technology based on non-thermal plasma (NTP). The process enables the co-production of renewable, low-carbon hydrogen and solid elemental carbon without direct CO2 emissions. ColdSpark® Phase II will accelerate and scale reactor design and operation, prepare a full-scale industrial deployment strategy, covering market engagement, regulatory compliance, and business modelling. By advancing this innovative NTP technology towards industrial readiness, the project supports the EU’s new resilience programs which aims to secure a reliable and affordable energy supply, and establish a cost-competitive, environmentally sustainable pathway for clean hydrogen and valuable carbon materials in Europe’s green energy transition, and is also in line with Hydrogen Europes’s strategies. ColdSpark® is more than H2 technology; it's a strategic enabler of Europe’s energy autonomy and resilience. Despite strong political ambitions, clean H2 remains too expensive and unavailable at scale - threatening Europe’s decarbonisation goals, industrial resilience, and strategic autonomy. From the user’s perspective, continued fossil fuel use perpetuates pollution, climate impacts, and energy vulnerability. Carbon black (CB) and graphite are among the most valuable chemical commodities, offering techno-economic advantages. Replacing fossil-based carbon is a major decarbonisation challenge, and many industries face growing uncertainty over coal supply as Europe phases out fossil fuels. Despite ongoing R&D, no scalable, sustainable carbon alternative currently exists.

Keywords: hydrogen elemental carbon non thermal plasma high voltage power supplies seidpower
Healthy, Sustainable and Scalable food from ocean grown seaweed (PerfectFood)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Faroe Islands
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 48.0
Total project cost (EUR): 1250000.0
EU funding (EUR): 1250000.0
Participants: 1
Project status: SIGNED

With our proposal, we want to address the EIC Challenge IV.2.4 “Food from precision fermentation and algae” as we aim to accelerate new algal market opportunities and at the same time contribute to solve some of today’s most urgent problems. Ocean Rainforest’s purpose is to improve people’s wellbeing and to make a unique, sustainable and scalable contribution to our blue planet. Our goal is to become the fastest-growing macroalgal producer in Europe and North America reaching 300,000 tonnes (wet weight) production from cultivation at sea and 1 Mio. tonnes (ww) through Sale, Scale and Source by 2030. We will do this by improving operational performance, optimising product-specific processing methods within fermentation and stabilisation, and strategic market development to turn seaweed biomass into healthy functional food ingredients and feed supplements. Through this, Ocean Rainforest will help fulfil the United Nations Sustainable Development Goals (specifically no. 3, 8, 9, 12, 13 & 14) with the long-term goal of doubling the world production of seaweed in the year 2050 (33 Mio T ww, FAO 2018). We believe this to be possible because, since 2014 we have designed, operated, and scaled cultivation structures that have been proven viable under nearshore highly exposed conditions in both the Faroe Islands and the United States. The cultivation technology is scalable and survivable in open oceans with higher growth rates and lower costs than other known offshore systems for similar seaweed species. Our innovative direct seeding methods and multiple partial harvest approaches have proven to be key for a commercial operation.

Keywords: fermentation,seaweed,kelp,saccharina,offshore,scaling,blue biomass,technology development,faroe islands
G0. SYSTEM, REVOLUTIONIZING ENDOVASCULAR PROCEDURES WITH MECHATRONICS (BCV)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2490000.0
EU funding (EUR): 2490000.0
Participants: 1
Project status: SIGNED

Basecamp Vascular (Bcv) is set to transform endovascular interventions, especially for stroke and aneurysm treatment, which affect 15 million people annually, causing 5 million permanent disabilities. Traditional procedures are complex, requiring multiple devices, leading to higher complication risks, longer hospital stays, and increased healthcare costs. Inefficiencies in navigation can cause vessel perforation, bleeding, and stroke recurrence, worsening outcomes and straining healthcare resources. Bcv’s Active Navigation System solution features unique mechatronic guidewire technology with Shape Memory Alloy (SMA) actuators. This system ensures precision and control, enhancing navigation through complex vascular pathways. It incorporates advanced materials, electro-active polymers, and real-time wire tip flexion, improving usability and precision during lengthy procedures. The system offers significant benefits, especially for complex cases linked to an aging population. It can reduce procedure times by up to 30%, lower complication risks by 30%, and enhance navigation accuracy. For medical centers, it can cut procedure costs by up to €2000, boost operational efficiency, and increase procedural throughput by 20-30%. For patients, it ensures safer, faster, and more effective minimally invasive interventions, leading to shorter hospital stays and quicker recoveries. Bcv’s innovation aims to revolutionize endovascular procedures, significantly improving patient outcomes and healthcare efficiency globally. This technology addresses crucial medical needs and offers substantial economic benefits, making it a compelling investment for the European EIC Accelerator.

Keywords: guidewire,minimally invasive interventions,endovascular therapy,stroke,interventional neuroradiology,neurovascular interventions
Healing hearts: Reverse and prevent heart failure with small molecules (Healing hearts)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Netherlands
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 2.5
EU funding (EUR): 2.5
Participants: 1
Project status: CLOSED

Saillant (established 2018, 4 employees) is developing an orally available small molecule (ST01) for reversing heart failure (HF) and preventing HF in at-risk patients (e.g. patients with diabetes, hypertension and myocardial infarction). Worldwide there are 64 million patients. HF is associated with poor quality of life and the 5-year survival rate is close to 50%. The global economic burden is estimated to reach $245 billion in 2030. Current therapies have very limited effects on survival rates and cannot cure HF. ST01 stimulates cardiomyocyte division in stressed, damaged heart tissue, not in healthy tissue. Saillant has proof of concept for cardiac function improvement and regeneration in animal models for diabetes (rats)- and myocardial infarction (mice, rats, minipigs)-induced heart failure. No adverse effects have been observed. All claims on the chemical structures on novelty, applicability and inventiveness have been granted by the European Patent Office. A curing HF therapy has blockbuster potential. A top 20 pharma company has performed due diligence on the biology and chemistry of ST01. The results were very positive. This company and 12 other big pharma companies indicated to be highly interested in a license when the results of a phase 1 trial are positive. In this project, Saillant will perform a phase 1a trial with healthy volunteers, a 6-month GLP tox study in rats and dogs and a phase 1b trial with diabetes- and myocardial infarction patients. In 2029, Saillant expects to conclude a license agreement with a big pharma company for further clinical development and commercialization. With the revenues, Saillant will be developed into a Netherlands-based, sustainable, pharmaceutical company where the preclinical-, and clinical research and commercialization will be under own management. In 2032, Saillant expects to have 4 running projects and 200 employees.

Keywords: heart failure,regeneration,small molecules,reverse,prevent
Boosting TalTech Capacity in Reliable and Efficient AI-Chip Design (TAICHIP)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Coordination and support actions
Panel: Information Science and Engineering
Countries involved: Estonia,Germany,France,Switzerland,United Kingdom
Call: Twinning Bottom-Up (HORIZON-WIDERA-2023-ACCESS-02, 2023)
Start date: 2024-09-01
End date: 2027-08-31
Duration (months): 36.0
Total project cost (EUR): 1234567.89
EU funding (EUR): 1234567.89
Participants: 5
Project status: SIGNED

Building on TalTech’s expertise in the field of computer engineering and its high-level capacity in the domain of diagnostics and testing of nanoelectronic systems, this project aims at establishing in TalTech, with the strong support of the Advanced Partners, the capacity to R&D&I a complete customised AI-chip design flow. The research ambition of the TAICHIP (TalTech AI-chip) action is a leading-edge forward-thinking R&D framework for reliable and resource-efficient custom AI-chips based on open HW architectures (e.g., RISC-V, NVDLA), open EDA (Electronic Design Automation) tools, methodologies and implementation technologies satisfying the requirements of AI applications of tomorrow. TAICHIP project also allows building at TalTech the necessary scientific knowledge, research skills, administrative and management skills, as well as strengthening its advanced training and education capacity. Evenly related to the central goal are the additional measures that focus on building the supporting capacities, as well as dissemination, exploitation and communication, and public policy focused activities.

Keywords: artificial intelligence,risc v,ai accelerator,asic,reliability,energy efficiency,open source,eu chips act
SAFE-ON Technology for Smart Antimicrobial Coatings (SAFE-ON)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Spain
Call: ERC PROOF OF CONCEPT GRANTS1 (ERC-2022-POC1, 2022)
Start date: 2022-05-01
End date: 2023-10-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Infectious diseases are a rapidly growing threat to humanity. For instance, the current COVID-19 pandemic, caused by the virus SARS-CoV-2, has already killed over 4.5 million people since 2019 and is taking a devastating socioeconomic toll around the world. Similarly, nosocomial infections are among the major causes of death and increased morbidity, causing thousands of deaths every year in Europe. Recently, the use of antimicrobial coatings has garnered increasing interest as a simple prophylactic strategy to combat these infectious diseases. In this PoC project, we aim advancing a new patented antimicrobial coating technology called SAFE-ON, into the pre-commercial stage, with the aim of demonstrating its breakthrough innovation potential and approaching its arrival to market. The first part of this project encompasses optimization of SAFE-ON technology as highly efficient, smart antimicrobial coatings. This entails the preparation of two antimicrobial coatings based on commercial formulations used in catheters and door-handle covers (one based on hydrogels and the other, on silicone), and subsequent testing of their antimicrobial capacity. It also involves preparing the first two SAFE-ON prototypes: one coated catheter and one door-handle cover. The second part of SAFE-ON will be dedicated to intellectual property (IP) and market aspects needed for the pre-commercialization of this new technology for antimicrobial coatings. This study will include a freedom-to-operate analysis and a market study to identify the antimicrobial coating producers that could ultimately serve as manufacturing partners. In this project we will design, fabricate and evaluate two innovative prototypes incorporating our iodine delivery platform, with the aim to assess the commercial viability of with antimicrobial SAFE-ON coatings, accelerate their market entry and ultimately, commercialize and further develop antimicrobial coatings and other biocide products based on our technology.